UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DCD.C. 20549

_______________________

FORM 8-K

_______________________

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~ SECTION 13 OR 15(d) OF ~~of the Securities and Exchange Act of 1934~~THE

~~Date of~~SECURITIES ~~Report~~EXCHANGE ~~(Date~~ACT ofOF ~~earliest reported): May 15, 2008~~1934

Date of report (Date of earliest event reported): February 16, 2010

_______________________

MAZAL PLANT PHARMACEUTICALS, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~charter~~Charter)

Nevada	000-27333	20-3761221
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

_______________________

43 West 33rd Street

Nevada		000-27333		20-3761221
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

New York, New York 10001

43 West 33rd Street New York, NY		10001
(Address of Principal Executive Offices)		(Zip Code)

(~~Address of principal executive offices~~212) ~~(Zip Code)~~ 444-1019

(Registrant'’s telephone number, including area code~~: (212~~) ~~695-3334~~

~~Check the~~Not ~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):~~applicable

~~[ ]~~(Former ~~Written~~Name ~~communications~~or ~~pursuant~~Former toAddress, ~~Rule~~if ~~425~~Changed ~~under~~Since ~~the~~Last ~~Securities Act (17 CFR 230.425~~Report)

~~[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)~~_______________________

~~[ ]~~Check the ~~Pre~~appropriate box below if the Form 8-~~commencement~~K ~~communications~~filing ~~pursuant~~is intended to ~~Rule~~simultaneously satisfy ~~14d-2(b)~~the ~~under~~filing obligation of the ~~Exchange~~registrant ~~Act (17~~under ~~CFR~~any ~~240.14d-2(b))~~of the following provisions:

~~[ ]~~o ~~Pre-commencement~~Written communications pursuant to Rule 425 ~~13e-4(c)~~ under the ~~Exchange~~Securities Act (17 CFR ~~240~~ 230.~~13e-4(c~~425)).

~~Item~~o Soliciting ~~8.01~~material ~~Other~~pursuant ~~Events~~to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Aso ~~previously~~Pre-commencement ~~disclosed,~~communications inpursuant ~~April 2008, shareholders of Mazal Plant Pharmaceuticals, Inc. (the “Company”) holding a majority of the outstanding shares of the Company (the “Majority Shareholders”) voted~~ to ~~remove Simcha Edell and Mechael Kanovsky as directors of the Company~~ Rule 14d-2(~~the “Terminated Directors”~~b)~~. Further, the Majority Shareholders also appoint Eliyahu~~ under ~~Tolchinsky as~~ the sole director. Mr. Tolchinsky, as the sole director of the Company, terminated all executive officers of the Company including Simcha Edell and Mechael Kanovsky. Mr. Tolchinsky was also appointed as the Chief Executive Officer, Chief Financial Officer, and Secretary of the Company. On May 14, 2008, Mr. Kanovsky, the former Chief Executive Officer of the Company, filed a Form 8K with the Securities and Exchange ~~Commission~~ ~~challenging~~Act ~~the~~(17 CFR ~~validity of the removal of the Terminated Directors and the termination of the executive officers~~240. ~~The filing of this Form 8K by Mr~~14d-2(b)). Kanovsky was not valid and was not authorized by the management of the Company. Further, the unauthorized filing by Mr. Kanovosky also indicated that the Company authorized the issuance of a series of preferred stock. The issuance of the preferred shares has not been authorized and is not a legitimate corporate action. The Company’s new web site is www.mazalpharmaceutical.com.

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Item 7.01. Regulation FD Disclosure.

Mazal Plant Pharmaceuticals Inc has completed a term sheet for an investment of $324,000 over 18 months with a average purchase price of 2 cents per share.

Mazal Plant Pharmaceutical Inc shareholders looking for current information can find it at the updated website www.mazalpharmaceutical.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MAZAL PHARMACEUTICALS, INC.
	MAZAL PLANT PHARMACEUTICALS, INC.
Date: May 15, 2008	By:	/s/ Eliyahu BenTal Tolchinsky
Date: February 16, 2010
		Name: Eliyahu Bental Tolchinsky
	By:	/s/ Chaim J. Lieberman
		Name: Chaim J. Lieberman
		Title: CEO

Filing Compare · Mazal Plant Pharmaceuticals, Inc